B.
Clinical significance.
✓
A.
The genetic marker directly causes the disease.
✓
B.
The genetic marker is associated with the disease, but confounding or other factors could be at play.
✓
C.
The study proves nothing.
✓
D.
Genetic markers are irrelevant.
✓
B.
Standardization of methods.
✓
D.
Patient recruitment.
✓
A.
Implement school closures indefinitely.
✓
B.
Launch a mass vaccination campaign and intensify communication efforts to address vaccine hesitancy.
✓
C.
Wait for the disease to naturally decline.
✓
D.
Isolate only symptomatic individuals.
✓
C.
Attributable Risk (AR).
✓
D.
Prevalence Ratio (PR).
✓
B.
Balancing drug benefits with potential harms through systematic risk identification and mitigation.
✓
C.
Marketing strategies.
✓
A.
Advise people to stay indoors.
✓
B.
Investigate potential environmental triggers (e.g., air pollution, allergen peaks) or an emerging respiratory pathogen.
✓
C.
Assume it is a normal seasonal fluctuation.
✓
D.
Only focus on treating individual patients.
✓
C.
Cumulative incidence.
✓
C.
Communicable period.
✓
C.
Pharmacoepidemiology.
✓
A.
The finding is highly important for public health.
✓
B.
Statistical significance does not always equate to clinical or public health significance.
✓
C.
The study was biased.
✓
D.
The sample size was too small.
✓
A.
Resistance patterns.
✓
B.
Local epidemiology of pathogens and their susceptibility.
✓
C.
Only individual patient symptoms.
✓
D.
The cost of the antibiotic.
✓
A.
Treat the patient and send them home.
✓
B.
Immediately initiate isolation, multi-drug therapy, and rigorous contact tracing to prevent widespread transmission.
✓
C.
Wait for the disease to spread to other family members.
✓
D.
Only treat the patient's symptoms.
✓
C.
Crude mortality rate.
✓
A.
Only efficacy matters.
✓
B.
The balance between benefits and harms, and informed consent for patients.
✓
C.
Adverse events are always acceptable.
✓
D.
Only the cost of the drug matters.
✓
B.
Information bias (e.g., misclassification due to self-report).
✓
